Literature DB >> 6480824

Effects of acetyl glyceryl ether of phosphorylcholine (platelet activating factor) on ventricular preload, afterload, and contractility in dogs.

J L Kenzora, J E Pérez, S R Bergmann, L G Lange.   

Abstract

Acetyl glyceryl ether of phosphorylcholine (AGEPC), platelet activating factor, is a potent hypotensive agent that may mediate changes in blood pressure during anaphylaxis and may be involved in blood pressure variations of renal origin. This study was designed to characterize the hemodynamic mechanisms responsible for hypotension induced by this recently identified phospholipid. Intravenous administration of AGEPC to anesthetized open-chest dogs (n = 5) produced hemodynamic alterations which, for the purpose of analysis, were divided into three phases based on changes in the mean systemic blood pressure. During phase I (5-30 s) mean systemic blood pressure decreased to levels 5 to 10% below baseline values in association with a rise in cardiac output and a decrease in systemic vascular resistance. Phase II (30-90 s) consisted of a substantial reduction in systemic blood pressure to its nadir, 50% of baseline values, together with a decrease of similar magnitude in cardiac output and a rise in systemic vascular resistance. Phase III (90 s-60 min) exhibited a gradual recovery of mean systemic blood pressure toward normal with a several-fold rise in systemic vascular resistance and a continued low cardiac output. On the right side of the circulation, the predominant effect of AGEPC was a marked transient increase in pulmonary artery pressure in phase I, associated with an elevation of pulmonary resistance during phase II. Diethylcarbamazine blocked virtually all of these hemodynamic changes induced by AGEPC; FPL 55712 substantially blocked the rise in systemic vascular resistance in phase III. These results suggest that leukotrienes may mediate at least some of the hemodynamic effects induced by AGEPC, but further studies will be required when more specific leukotriene blocking agents become available. As assessed during phase III with the end-systolic pressure-dimension relation, myocardial performance itself was diminished. The occurrence of an AGEPC-induced negative inotropic effect was further confirmed in isolated Krebs-perfused guinea pig hearts and isolated blood-perfused rabbit hearts. The results indicate that the mechanism of AGEPC-induced hypotension is complex, affecting both vascular tone and the inotropic state of the myocardium.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6480824      PMCID: PMC425285          DOI: 10.1172/JCI111528

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  LEFT VENTRICULAR DYNAMICS IN DOGS DURING ANESTHESIA WITH ALPHA-CHLORALOSE AND SODIUM PENTOBARBITAL.

Authors:  R L VANCITTERS; D L FRANKLIN; R F RUSHMER
Journal:  Am J Cardiol       Date:  1964-03       Impact factor: 2.778

2.  Analysis of leukotrienes by high-pressure liquid chromatography.

Authors:  W R Mathews; J Rokach; R C Murphy
Journal:  Anal Biochem       Date:  1981-11-15       Impact factor: 3.365

3.  Cardiac function and myocardial contractility: a perspective.

Authors:  J Ross
Journal:  J Am Coll Cardiol       Date:  1983-01       Impact factor: 24.094

4.  Nonimmunological production of leukotrienes induced by platelet-activating factor.

Authors:  N F Voelkel; S Worthen; J T Reeves; P M Henson; R C Murphy
Journal:  Science       Date:  1982-10-15       Impact factor: 47.728

5.  Chloralose anesthesia in the dog: a study of drug actions and analytical methodology.

Authors:  B G Bass; N M Buckley
Journal:  Am J Physiol       Date:  1966-04

6.  Analogs of phosphatidylcholine: alpha-adrenergic antagonists from the renal medulla.

Authors:  K A Smith; R L Prewitt; L W Byers; E E Muirhead
Journal:  Hypertension       Date:  1981 Jul-Aug       Impact factor: 10.190

7.  Acetyl glyceryl ether phosphorylcholine stimulates leukotriene B4 synthesis in human polymorphonuclear leukocytes.

Authors:  A H Lin; D R Morton; R R Gorman
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

8.  Acetyl glyceryl ether phosphorylcholine (AGEPC). A putative mediator of cardiac anaphylaxis in the guinea pig.

Authors:  R Levi; J A Burke; Z G Guo; Y Hattori; C M Hoppens; L M McManus; D J Hanahan; R N Pinckard
Journal:  Circ Res       Date:  1984-02       Impact factor: 17.367

9.  Studies on the interactions of acetyl glycerol ether phosphoryl choline with the sympathetic nervous system in rats.

Authors:  E J Sybertz; C Sabin; T Baum; E Eynon; S Nelson; R Moran
Journal:  J Pharmacol Exp Ther       Date:  1982-12       Impact factor: 4.030

10.  Fatty acid profiling of phospholipids by field desorption and fast atom bombardment mass spectrometry.

Authors:  W D Lehmann; M Kessler
Journal:  Chem Phys Lipids       Date:  1983-03       Impact factor: 3.329

View more
  18 in total

1.  Coronary vasoconstriction in the rat, isolated perfused heart induced by platelet-activating factor is mediated by leukotriene C4.

Authors:  P J Piper; A G Stewart
Journal:  Br J Pharmacol       Date:  1986-07       Impact factor: 8.739

Review 2.  Cardiovascular effects of platelet-activating factor.

Authors:  R E Goldstein; G Z Feuerstein; L M Bradley; J J Stambouly; F R Laurindo; N J Davenport
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

Review 3.  Cardiac dysfunction in sepsis: new theories and clinical implications.

Authors:  R M Grocott-Mason; A M Shah
Journal:  Intensive Care Med       Date:  1998-04       Impact factor: 17.440

4.  The pattern of cardiovascular alterations induced by infusion of platelet-activating factor in rabbit is modified by pretreatment with H1-H2 receptor antagonists but not by cyclooxygenase inhibition.

Authors:  G Montrucchio; G Alloatti; F Mariano; E Meda; C Tetta; G Emanuelli; G Camussi
Journal:  Agents Actions       Date:  1987-06

5.  Molecular and cellular actions of platelet-activating factor in rat heart cells.

Authors:  C V Massey; T A Kohout; S T Gaa; W J Lederer; T B Rogers
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

Review 6.  Platelet activating factor in heart failure: potential role in disease progression and novel target for therapy.

Authors:  Paraskevi Detopoulou; Tzortzis Nomikos; Elizabeth Fragopoulou; Christina Chrysohoou; Smaragdi Antonopoulou
Journal:  Curr Heart Fail Rep       Date:  2013-06

7.  Kinetics of acetyl glyceryl ether phosphorylcholine (AGEPC)-induced acute lung alterations in the rabbit.

Authors:  L M McManus; R N Pinckard
Journal:  Am J Pathol       Date:  1985-10       Impact factor: 4.307

8.  Cultured endothelial cells synthesize both platelet-activating factor and prostacyclin in response to histamine, bradykinin, and adenosine triphosphate.

Authors:  T M McIntyre; G A Zimmerman; K Satoh; S M Prescott
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

9.  Effect of the platelet-activating factor antagonist, TCV-309, and the cyclo-oxygenase inhibitor, ibuprofen, on the haemodynamic changes in canine experimental endotoxic shock.

Authors:  S Yamanaka; H Iwao; T Yukimura; S Kim; K Miura
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

10.  Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor.

Authors:  G Ambrosio; A Oriente; C Napoli; G Palumbo; P Chiariello; G Marone; M Condorelli; M Chiariello; M Triggiani
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.